Provider Briefing: Budesonide XR Supply in 2026

If your patients have been reporting difficulty filling prescriptions for Budesonide extended-release capsules (Entocort EC, Ortikos, generic), the problem is real and ongoing. Supply disruptions have affected availability of oral Budesonide capsules intermittently since 2023, and the situation remains unresolved in 2026.

This briefing covers the current state of the Budesonide XR shortage, its clinical implications, available alternatives, and resources to help you and your patients navigate the situation.

Shortage Timeline and Current Status

Budesonide extended-release capsules (3 mg, 6 mg, 9 mg) have experienced recurring supply disruptions driven by manufacturing consolidation, raw material sourcing challenges, and increased demand.

Key Timeline Points

• 2023: Initial reports of intermittent supply issues with generic Budesonide capsules. Multiple manufacturers experienced production disruptions.
• 2024: Supply remained inconsistent. Some pharmacies reported adequate stock while others faced weeks-long backorders. The FDA drug shortage database intermittently listed Budesonide.
• 2025: Generic market consolidation continued. Increased off-label prescribing for microscopic colitis and autoimmune hepatitis contributed to demand pressure.
• 2026 (current): Availability remains regional and inconsistent. The oral capsule formulation is most affected. Extended-release tablets (Uceris) and inhalation products (Pulmicort) have been less impacted but are not therapeutically interchangeable with the capsules.

The shortage does not currently meet FDA criteria for a critical shortage listing, but supply remains unreliable in many markets.

Prescribing Implications

The intermittent nature of this shortage creates several clinical challenges:

Treatment Interruptions

Patients with active Crohn's disease who cannot fill their Budesonide XR prescription face potential disease flares. Abrupt discontinuation of corticosteroids also carries the risk of adrenal insufficiency, particularly in patients who have been on therapy for more than a few weeks.

Formulation Confusion

Patients may present with questions about switching between Budesonide formulations. It's important to counsel that:

• Extended-release capsules (Entocort EC/Ortikos) release medication in the ileum and ascending colon — appropriate for Crohn's disease
• Extended-release tablets (Uceris) release medication throughout the colon — indicated for ulcerative colitis
• Delayed-release capsules (Tarpeyo) are designed for IgA nephropathy
• These formulations are not interchangeable

Dose Substitution Considerations

When the prescribed strength is unavailable, dose-equivalent substitution using a different capsule strength may be appropriate. For example, three 3 mg capsules may substitute for one 9 mg dose if the 9 mg capsules are out of stock. This requires a new prescription.

Current Availability Picture

Availability varies significantly by:

• Geographic region: Urban areas with more pharmacy options generally have better access
• Pharmacy type: Independent pharmacies and specialty pharmacies may have stock when chain pharmacies do not
• Wholesaler relationships: Pharmacies with access to multiple wholesalers have more sourcing flexibility
• Formulation and strength: 3 mg capsules tend to be more available than 6 mg or 9 mg capsules

Medfinder for Providers offers real-time pharmacy availability data that can help you direct patients to pharmacies with current stock.

Cost and Access Considerations

Even when available, cost can be a barrier for uninsured or underinsured patients:

• Generic Budesonide 3 mg capsules (30-day supply): $50–$150 cash price; $40–$90 with discount cards (GoodRx, SingleCare)
• Brand Entocort EC: $800–$1,200
• Brand Uceris (tablets): $1,200–$1,800

For patients facing cost barriers, discount card programs and patient assistance programs through NeedyMeds, RxAssist, and Simplefill may provide relief. Our patient-facing guide on saving money on Budesonide XR can be shared with patients directly.

Alternative Therapies

When Budesonide XR is unavailable, the following alternatives may be considered based on clinical context:

For Active Mild-to-Moderate Crohn's Disease

• Prednisone (40 mg daily, tapered over 8–12 weeks): Effective but carries significantly more systemic side effects. Consider for short-term bridge therapy when Budesonide is unavailable. Cost: $4–$10 for a 30-day supply.
• Prednisolone: Bioactive form of Prednisone. May be preferred in patients with hepatic impairment. Available in liquid form. Cost: $10–$30.
• Methylprednisolone: Alternative systemic corticosteroid. Oral or IV formulations available. Cost: $15–$40 (oral).

For Maintenance of Remission

• Mesalamine (5-ASA agents): May be considered for mild colonic Crohn's disease, though evidence for efficacy in Crohn's maintenance is limited compared to UC.
• Immunomodulators (Azathioprine, 6-Mercaptopurine): Established maintenance therapy for Crohn's disease.
• Biologics (Adalimumab, Infliximab, Ustekinumab, Vedolizumab): For patients who require escalation beyond corticosteroid therapy.

For a patient-facing overview of these options, direct patients to our article on alternatives to Budesonide XR.

Tools and Resources for Your Practice

Medfinder for Providers

Medfinder for Providers helps you:

• Check real-time Budesonide XR availability at pharmacies near your patients
• Direct patients to specific pharmacies with current stock
• Reduce phone call volume from patients struggling to fill prescriptions

Patient Education Resources

Consider sharing these articles with affected patients:

• How to find Budesonide XR in stock near you
• Budesonide XR shortage update for patients
• Budesonide XR drug interactions

FDA Drug Shortage Database

Monitor the FDA Drug Shortage Database for official shortage listings and estimated resupply dates.

Looking Ahead

The Budesonide XR supply situation is expected to improve gradually as generic manufacturers increase production capacity. However, the structural issues driving the shortage — market consolidation, rising demand, and complex global supply chains — are unlikely to resolve quickly.

Proactive communication with patients about potential supply issues, early refill planning, and familiarity with alternative regimens will help your practice manage through continued availability challenges.

Final Thoughts

The Budesonide XR shortage is a manageable clinical challenge, but it requires awareness and planning. By leveraging tools like Medfinder for Providers, staying informed about available alternatives, and proactively communicating with patients, you can minimize treatment disruptions and maintain quality care for your IBD patients.